This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
ReNeuron Group plc
Drug Names(s): CTX0E03 cells, ReN009 stem cell therapy, ReN-009
Description: ReN009 cell therapy consists of a neural cell line, designated CTX, that has been generated using ReNeuron's proprietary cell expansion and cell selection technologies.
The cell line used, CTX0E03, is a conditionally immortalized neural human stem cell line derived from 13-week gestation fetal cortex. The cell line is clonal as a result of conditional immortalisation with c-mycER TAM, which confers augmented culture expansion with genetic stability upon supplementation of 4-hydroxytamoxifen in the culture medium.
Additional information available to subscribers only: